BioLine RX Altman Z-Score
The Altman Z-Score of BioLine RX (BLRX.TA) as of Sep 3, 2026 is -14.19. In the previous year, Altman Z-Score was -10.16 — a change of 39.68% (lower).
Get this data via API
Financial Data API
Altman Z-Score
-14.19
YoY
39.68%
Last updated:
Altman Z-Score of BioLine RX is 2026 -14.19 . Altman Z-Score of BioLine RX was 2025 -10.16 . It decreases by 39.68% lower compared to the previous year.
The BioLine RX Altman Z-Score history
3 Years
10 Years
25 Years
Max
Altman Z-Score
Date
Altman Z-Score
Jan 1, 2017
-4.84 USD
Jan 1, 2018
-6.27 USD
Jan 1, 2019
-7.55 USD
Jan 1, 2020
-9.19 USD
Jan 1, 2021
-5.48 USD
Jan 1, 2022
-6.73 USD
Jan 1, 2023
-10.16 USD
Jan 1, 2024
-14.19 USD
| YEAR | Altman Z-Score | YoY |
|---|---|---|
| -14.19 | +39.68% | |
| -10.16 | +50.80% | |
| -6.73 | +22.96% | |
| -5.48 | -40.37% | |
| -9.19 | +21.73% | |
| -7.55 | +20.32% | |
| -6.27 | +29.64% | |
| -4.84 | -12.25% | |
| -5.51 | +73.13% | |
| -3.18 | -38.60% | |
| -5.19 | — |
Access this data via the Eulerpool API
BioLine RX Stock analysis
What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.
Frequently Asked Questions about BioLine RX stock
Altman Z-Score of BioLine RX is -14.19 in 2026.
On Eulerpool you can find the complete historical development of Altman Z-Score BioLine RX since 2006 – with annual values, charts, and detailed analysis.
The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.
Access this data via the Eulerpool API
Quality — BioLine RX
All Key Metrics — BioLine RX
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth